Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists
Food and Drug Administration to continuously monitor the safety profile of our medicines
Enfermedad biliar (colelitiasis/colecistitis): Un meta-anlisis de 76 ensayos clnicos randomizados muestra RR 1,37 (mayor riesgo a dosis altas , uso prolongado y cuando se usan para prdida de peso
D.UmpierrezG
Riboflavin treatment in a case with l-2-hydroxyglutaric aciduria
Interestingly, these pharmacological concentrations align closely with peak levels of endogenous GLP-1 observed during intense physiological stimulation [120, 121]